Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hepatocellular Carcinoma-Pipeline Review, H1 2015

Hepatocellular Carcinoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hepatocellular Carcinoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hepatocellular Carcinoma-Pipeline Review, H1 2015', provides an overview of the Hepatocellular Carcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hepatocellular Carcinoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hepatocellular Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 8

Hepatocellular Carcinoma Overview 9

Therapeutics Development 10

Hepatocellular Carcinoma-Therapeutics under Development by Companies 12

Hepatocellular Carcinoma-Therapeutics under Investigation by Universities/Institutes 22

Hepatocellular Carcinoma-Pipeline Products Glance 25

Hepatocellular Carcinoma-Products under Development by Companies 28

Hepatocellular Carcinoma-Products under Investigation by Universities/Institutes 40

Hepatocellular Carcinoma-Companies Involved in Therapeutics Development 42

Hepatocellular Carcinoma-Therapeutics Assessment 152

Drug Profiles 171

Hepatocellular Carcinoma-Recent Pipeline Updates 520

Hepatocellular Carcinoma-Dormant Projects 752

Hepatocellular Carcinoma-Discontinued Products 760

Hepatocellular Carcinoma-Product Development Milestones 763

Appendix 770

List of Tables

Number of Products under Development for Hepatocellular Carcinoma, H1 2015 30

Number of Products under Development for Hepatocellular Carcinoma-Comparative Analysis, H1 2015 31

Number of Products under Development by Companies, H1 2015 33

Number of Products under Development by Companies, H1 2015 (Contd..1) 34

Number of Products under Development by Companies, H1 2015 (Contd..2) 35

Number of Products under Development by Companies, H1 2015 (Contd..3) 36

Number of Products under Development by Companies, H1 2015 (Contd..4) 37

Number of Products under Development by Companies, H1 2015 (Contd..5) 38

Number of Products under Development by Companies, H1 2015 (Contd..6) 39

Number of Products under Development by Companies, H1 2015 (Contd..7) 40

Number of Products under Development by Companies, H1 2015 (Contd..8) 41

Number of Products under Investigation by Universities/Institutes, H1 2015 43

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44

Comparative Analysis by Late Stage Development, H1 2015 45

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Development, H1 2015 47

Products under Development by Companies, H1 2015 48

Products under Development by Companies, H1 2015 (Contd..1) 49

Products under Development by Companies, H1 2015 (Contd..2) 50

Products under Development by Companies, H1 2015 (Contd..3) 51

Products under Development by Companies, H1 2015 (Contd..4) 52

Products under Development by Companies, H1 2015 (Contd..5) 53

Products under Development by Companies, H1 2015 (Contd..6) 54

Products under Development by Companies, H1 2015 (Contd..7) 55

Products under Development by Companies, H1 2015 (Contd..8) 56

Products under Development by Companies, H1 2015 (Contd..9) 57

Products under Development by Companies, H1 2015 (Contd..10) 58

Products under Development by Companies, H1 2015 (Contd..11) 59

Products under Investigation by Universities/Institutes, H1 2015 60

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 61

Hepatocellular Carcinoma-Pipeline by 4SC AG, H1 2015 62

Hepatocellular Carcinoma-Pipeline by AbbVie Inc., H1 2015 63

Hepatocellular Carcinoma-Pipeline by Acceleron Pharma, Inc., H1 2015 64

Hepatocellular Carcinoma-Pipeline by Active Biotech AB, H1 2015 65

Hepatocellular Carcinoma-Pipeline by Adaptimmune Limited, H1 2015 66

Hepatocellular Carcinoma-Pipeline by Advenchen Laboratories, LLC, H1 2015 67

Hepatocellular Carcinoma-Pipeline by Alfact Innovation, H1 2015 68

Hepatocellular Carcinoma-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 69

Hepatocellular Carcinoma-Pipeline by Amgen Inc., H1 2015 70

Hepatocellular Carcinoma-Pipeline by AndroScience Corporation, H1 2015 71

Hepatocellular Carcinoma-Pipeline by ArQule, Inc., H1 2015 72

Hepatocellular Carcinoma-Pipeline by Array BioPharma Inc., H1 2015 73

Hepatocellular Carcinoma-Pipeline by Arrowhead Research Corporation, H1 2015 74

Hepatocellular Carcinoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 75

Hepatocellular Carcinoma-Pipeline by AstraZeneca Plc, H1 2015 76

Hepatocellular Carcinoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 77

Hepatocellular Carcinoma-Pipeline by Bayer AG, H1 2015 78

Hepatocellular Carcinoma-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 79

Hepatocellular Carcinoma-Pipeline by Bioneer Corporation, H1 2015 80

Hepatocellular Carcinoma-Pipeline by Blueprint Medicines, H1 2015 81

Hepatocellular Carcinoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 82

Hepatocellular Carcinoma-Pipeline by Boston Biomedical, Inc., H1 2015 83

Hepatocellular Carcinoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 84

Hepatocellular Carcinoma-Pipeline by Caladrius Biosciences, Inc. , H1 2015 85

Hepatocellular Carcinoma-Pipeline by Can-Fite BioPharma Ltd., H1 2015 86

Hepatocellular Carcinoma-Pipeline by CASI Pharmaceuticals Inc., H1 2015 87

Hepatocellular Carcinoma-Pipeline by CCRP Therapeutics GmbH, H1 2015 88

Hepatocellular Carcinoma-Pipeline by Celgene Corporation, H1 2015 89

Hepatocellular Carcinoma-Pipeline by Celsion Corporation, H1 2015 90

Hepatocellular Carcinoma-Pipeline by China Medical System Holdings Limited, H1 2015 91

Hepatocellular Carcinoma-Pipeline by Chroma Therapeutics Limited, H1 2015 92

Hepatocellular Carcinoma-Pipeline by CrystalGenomics, Inc., H1 2015 93

Hepatocellular Carcinoma-Pipeline by CytRx Corporation, H1 2015 94

Hepatocellular Carcinoma-Pipeline by Delcath Systems, Inc., H1 2015 95

Hepatocellular Carcinoma-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 96

Hepatocellular Carcinoma-Pipeline by Digna Biotech, S.L., H1 2015 97

Hepatocellular Carcinoma-Pipeline by e-Therapeutics Plc, H1 2015 98

Hepatocellular Carcinoma-Pipeline by Eisai Co., Ltd., H1 2015 99

Hepatocellular Carcinoma-Pipeline by Eli Lilly and Company, H1 2015 100

Hepatocellular Carcinoma-Pipeline by Endocyte, Inc., H1 2015 101

Hepatocellular Carcinoma-Pipeline by Exelixis, Inc., H1 2015 102

Hepatocellular Carcinoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 103

Hepatocellular Carcinoma-Pipeline by Gamida Cell Ltd., H1 2015 104

Hepatocellular Carcinoma-Pipeline by Genelux Corporation, H1 2015 105

Hepatocellular Carcinoma-Pipeline by Genoscience Pharma, H1 2015 106

Hepatocellular Carcinoma-Pipeline by GenSpera, Inc., H1 2015 107

Hepatocellular Carcinoma-Pipeline by GlaxoSmithKline Plc, H1 2015 108

Hepatocellular Carcinoma-Pipeline by Immune Network, Ltd., H1 2015 109

Hepatocellular Carcinoma-Pipeline by Immunicum AB, H1 2015 110

Hepatocellular Carcinoma-Pipeline by Immunomedics, Inc., H1 2015 111

Hepatocellular Carcinoma-Pipeline by Immunovative Therapies, Ltd., H1 2015 112

Hepatocellular Carcinoma-Pipeline by Immuron Limited, H1 2015 113

Hepatocellular Carcinoma-Pipeline by In Cell Art, H1 2015 114

Hepatocellular Carcinoma-Pipeline by Incuron, LLC, H1 2015 115

Hepatocellular Carcinoma-Pipeline by Intezyne, Inc, H1 2015 116

Hepatocellular Carcinoma-Pipeline by Johnson & Johnson, H1 2015 117

Hepatocellular Carcinoma-Pipeline by KAHR medical Ltd., H1 2015 118

Hepatocellular Carcinoma-Pipeline by Komipharm International Co., Ltd., H1 2015 119

Hepatocellular Carcinoma-Pipeline by Kowa Company, Ltd., H1 2015 120

Hepatocellular Carcinoma-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 121

Hepatocellular Carcinoma-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 122

Hepatocellular Carcinoma-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 123

Hepatocellular Carcinoma-Pipeline by MaxCyte, Inc., H1 2015 124

Hepatocellular Carcinoma-Pipeline by MedImmune, LLC, H1 2015 125

Hepatocellular Carcinoma-Pipeline by Medivation, Inc., H1 2015 126

Hepatocellular Carcinoma-Pipeline by Merck KGaA, H1 2015 127

Hepatocellular Carcinoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 128

Hepatocellular Carcinoma-Pipeline by Mirna Therapeutics, Inc., H1 2015 129

Hepatocellular Carcinoma-Pipeline by MolMed S.p.A., H1 2015 130

Hepatocellular Carcinoma-Pipeline by MultiCell Technologies, Inc., H1 2015 131

Hepatocellular Carcinoma-Pipeline by Nerviano Medical Sciences S.r.l., H1 2015 132

Hepatocellular Carcinoma-Pipeline by Nimbus Therapeutics, LLC, H1 2015 133

Hepatocellular Carcinoma-Pipeline by Novartis AG, H1 2015 134

Hepatocellular Carcinoma-Pipeline by Nymox Pharmaceutical Corporation, H1 2015 135

Hepatocellular Carcinoma-Pipeline by Omeros Corporation, H1 2015 136

Hepatocellular Carcinoma-Pipeline by Oncolys BioPharma Inc., H1 2015 137

Hepatocellular Carcinoma-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 138

Hepatocellular Carcinoma-Pipeline by OncoTherapy Science, Inc., H1 2015 139

Hepatocellular Carcinoma-Pipeline by Oncothyreon Inc., H1 2015 140

Hepatocellular Carcinoma-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 141

Hepatocellular Carcinoma-Pipeline by Onxeo SA, H1 2015 142

Hepatocellular Carcinoma-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 143

Hepatocellular Carcinoma-Pipeline by Otsuka Holdings Co., Ltd., H1 2015 144

Hepatocellular Carcinoma-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 145

Hepatocellular Carcinoma-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 146

Hepatocellular Carcinoma-Pipeline by Pfizer Inc., H1 2015 147

Hepatocellular Carcinoma-Pipeline by Pharma Mar, S.A., H1 2015 148

Hepatocellular Carcinoma-Pipeline by PharmAbcine, Inc., H1 2015 149

Hepatocellular Carcinoma-Pipeline by PhaseRx, Inc., H1 2015 150

Hepatocellular Carcinoma-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 151

Hepatocellular Carcinoma-Pipeline by Priaxon AG, H1 2015 152

Hepatocellular Carcinoma-Pipeline by Progen Pharmaceuticals Limited, H1 2015 153

Hepatocellular Carcinoma-Pipeline by Provecs Medical GmbH, H1 2015 154

Hepatocellular Carcinoma-Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 155

Hepatocellular Carcinoma-Pipeline by Raptor Pharmaceuticals Corp., H1 2015 156

Hepatocellular Carcinoma-Pipeline by Regulus Therapeutics Inc., H1 2015 157

Hepatocellular Carcinoma-Pipeline by Rigontec GmbH, H1 2015 158

Hepatocellular Carcinoma-Pipeline by Shenogen Pharma Group Ltd., H1 2015 159

Hepatocellular Carcinoma-Pipeline by Synta Pharmaceuticals Corp., H1 2015 160

Hepatocellular Carcinoma-Pipeline by Taiwan Liposome Company, Ltd., H1 2015 161

Hepatocellular Carcinoma-Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 162

Hepatocellular Carcinoma-Pipeline by Therapure Biopharma Inc., H1 2015 163

Hepatocellular Carcinoma-Pipeline by Theravectys S.A., H1 2015 164

Hepatocellular Carcinoma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 165

Hepatocellular Carcinoma-Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2015 166

Hepatocellular Carcinoma-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 167

Hepatocellular Carcinoma-Pipeline by VasGene Therapeutics, Inc., H1 2015 168

Hepatocellular Carcinoma-Pipeline by Vaxon Biotech, H1 2015 169

Hepatocellular Carcinoma-Pipeline by Vicus Therapeutics, LLC, H1 2015 170

Hepatocellular Carcinoma-Pipeline by Virttu Biologics Limited, H1 2015 171

Assessment by Monotherapy Products, H1 2015 172

Assessment by Combination Products, H1 2015 173

Number of Products by Stage and Target, H1 2015 175

Number of Products by Stage and Mechanism of Action, H1 2015 182

Number of Products by Stage and Route of Administration, H1 2015 188

Number of Products by Stage and Molecule Type, H1 2015 190

Hepatocellular Carcinoma Therapeutics-Recent Pipeline Updates, H1 2015 539

Hepatocellular Carcinoma-Dormant Projects, H1 2015 771

Hepatocellular Carcinoma-Dormant Projects (Contd..1), H1 2015 772

Hepatocellular Carcinoma-Dormant Projects (Contd..2), H1 2015 773

Hepatocellular Carcinoma-Dormant Projects (Contd..3), H1 2015 774

Hepatocellular Carcinoma-Dormant Projects (Contd..4), H1 2015 775

Hepatocellular Carcinoma-Dormant Projects (Contd..5), H1 2015 776

Hepatocellular Carcinoma-Dormant Projects (Contd..6), H1 2015 777

Hepatocellular Carcinoma-Dormant Projects (Contd..7), H1 2015 778

Hepatocellular Carcinoma-Discontinued Products, H1 2015 779

Hepatocellular Carcinoma-Discontinued Products (Contd..1), H1 2015 780

Hepatocellular Carcinoma-Discontinued Products (Contd..2), H1 2015 781

List of Figures

Number of Products under Development for Hepatocellular Carcinoma, H1 2015 30

Number of Products under Development for Hepatocellular Carcinoma-Comparative Analysis, H1 2015 31

Number of Products under Development by Companies, H1 2015 32

Number of Products under Investigation by Universities/Institutes, H1 2015 42

Comparative Analysis by Clinical Stage Development, H1 2015 46

Comparative Analysis by Early Stage Products, H1 2015 47

Assessment by Monotherapy Products, H1 2015 172

Assessment by Combination Products, H1 2015 173

Number of Products by Top 10 Targets, H1 2015 174

Number of Products by Stage and Top 10 Targets, H1 2015 174

Number of Products by Top 10 Mechanism of Actions, H1 2015 181

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 181

Number of Products by Top 10 Routes of Administration, H1 2015 187

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 187

Number of Products by Top 10 Molecule Types, H1 2015 189

Number of Products by Stage and Top 10 Molecule Types, H1 2015 189

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Acceleron Pharma, Inc.

Active Biotech AB

Adaptimmune Limited

Advenchen Laboratories, LLC

Alfact Innovation

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

AndroScience Corporation

ArQule, Inc.

Array BioPharma Inc.

Arrowhead Research Corporation

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Bayer AG

Bio-Cancer Treatment International Limited

Bioneer Corporation

Blueprint Medicines

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Caladrius Biosciences, Inc.

Can-Fite BioPharma Ltd.

CASI Pharmaceuticals Inc.

CCRP Therapeutics GmbH

Celgene Corporation

Celsion Corporation

China Medical System Holdings Limited

Chroma Therapeutics Limited

CrystalGenomics, Inc.

CytRx Corporation

Delcath Systems, Inc.

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

e-Therapeutics Plc

Eisai Co., Ltd.

Eli Lilly and Company

Endocyte, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Gamida Cell Ltd.

Genelux Corporation

Genoscience Pharma

GenSpera, Inc.

GlaxoSmithKline Plc

Immune Network, Ltd.

Immunicum AB

Immunomedics, Inc.

Immunovative Therapies, Ltd.

Immuron Limited

In Cell Art

Incuron, LLC

Intezyne, Inc

Johnson & Johnson

KAHR medical Ltd.

Komipharm International Co., Ltd.

Kowa Company, Ltd.

Kyowa Hakko Kirin Co., Ltd.

Ligand Pharmaceuticals, Inc.

Lixte Biotechnology Holdings, Inc.

MaxCyte, Inc.

MedImmune, LLC

Medivation, Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

MolMed S.p.A.

MultiCell Technologies, Inc.

Nerviano Medical Sciences S.r.l.

Nimbus Therapeutics, LLC

Novartis AG

Nymox Pharmaceutical Corporation

Omeros Corporation

Oncolys BioPharma Inc.

OncoMed Pharmaceuticals, Inc.

OncoTherapy Science, Inc.

Oncothyreon Inc.

Ono Pharmaceutical Co., Ltd.

Onxeo SA

Onyx Pharmaceuticals, Inc.

Otsuka Holdings Co., Ltd.

Panacea Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharma Mar, S.A.

PharmAbcine, Inc.

PhaseRx, Inc.

Polaris Pharmaceuticals, Inc.

Priaxon AG

Progen Pharmaceuticals Limited

Provecs Medical GmbH

Provectus Biopharmaceuticals, Inc.

Raptor Pharmaceuticals Corp.

Regulus Therapeutics Inc.

Rigontec GmbH

Shenogen Pharma Group Ltd.

Synta Pharmaceuticals Corp.

Taiwan Liposome Company, Ltd.

Tekmira Pharmaceuticals Corp.

Therapure Biopharma Inc.

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

Toko Pharmaceutical Industries Co., Ltd.

TRACON Pharmaceuticals, Inc.

VasGene Therapeutics, Inc.

Vaxon Biotech

Vicus Therapeutics, LLC

Virttu Biologics Limited

Hepatocellular Carcinoma Therapeutic Products under Development, Key Players in Hepatocellular Carcinoma Therapeutics, Hepatocellular Carcinoma Pipeline Overview, Hepatocellular Carcinoma Pipeline, Hepatocellular Carcinoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com